Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study High levels of DNA replication stress and defects in the ...

ORIC Pharmaceuticals, Inc. announced its clinical development plans for its lead programs, ORIC-944 and ORIC-114, while reporting financial results for the first quarter of 2025. The company presented ...

Researchers have developed a three-step plan to support those burdened by the intense fear of cancer returning. This plan offers a consistent, streamlined approach to managing recurrence anxiety, ...

Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer, ...

Expanding the Multidisciplinary Team in Prediagnostic Care of Lung Cancer: How Else Can We Improve Time to Targeted Treatment in Metastatic Non–Small-Cell Lung Cancer? In the article that accompanies ...

Boehringer Ingelheim and the Lower Franconian biotech company EMFRET Analytics have signed a cooperation and license agreement for the preclinical development program of the GPVI‑blocking antibody ...

This podcast from the 2023 IO360º conference focuses on key learnings from the full clinical development pathway for approved autologous cell therapy products, from first-in-human, through launch, to ...

Kymera Therapeutics has announced that Sanofi will advance their next-generation oral IRAK4 degrader, KT-485, into clinical testing, while opting not to pursue KT-474. Preclinical studies indicated ...

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced Dr.

STAMFORD, Conn. and BASEL, Switzerland and BEIJING and CAMBRIDGE, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (SWTX), and BeiGene, Ltd ...